EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026

Key Takeaways

• EMA’s CHMP committee recommended five new medicines for approval during its April 20-23, 2026 meeting
• Tolebrutinib (brand name Cenrifki) was among the key medicines receiving positive recommendation
• Final approval decisions from the European Commission are expected in the coming months following CHMP recommendations

---

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) delivered positive recommendations for five new medicines during its April 20-23, 2026 meeting, marking a significant milestone for patients awaiting new treatment options across Europe.

Major Approvals Include Multiple Sclerosis Treatment

Among the notable recommendations was tolebrutinib, marketed under the brand name Cenrifki, which represents a potential breakthrough in multiple sclerosis treatment. Tolebrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that has shown promise in clinical trials for treating both relapsing and progressive forms of multiple sclerosis.

The CHMP’s positive opinion on tolebrutinib follows extensive clinical evaluation demonstrating its efficacy in reducing disease activity and slowing disability progression in MS patients. This oral medication offers a new mechanism of action that could provide an alternative for patients who have not responded adequately to existing therapies.

Regulatory Process and Timeline

The CHMP recommendations now advance to the European Commission for final marketing authorization decisions. Typically, the European Commission follows CHMP recommendations and grants approval within 67 days of receiving the positive opinion.

These approvals reflect the EMA’s continued commitment to bringing innovative treatments to European patients while maintaining rigorous safety and efficacy standards. The April meeting statistics demonstrate robust regulatory activity, with multiple therapeutic areas represented among the recommended medicines.

Market Impact and Patient Access

The approval of these five medicines, particularly tolebrutinib for multiple sclerosis, could significantly impact treatment landscapes across Europe. Multiple sclerosis affects approximately 700,000 people in Europe, and new treatment options are critically needed for patients with progressive disease forms.

Once approved, these medicines will undergo national pricing and reimbursement negotiations in individual EU member states, which will determine patient access timelines and affordability across different European healthcare systems.

---

Frequently Asked Questions

What does this CHMP recommendation mean for patients?

CHMP recommendations are the final step before European Commission approval. Patients can expect these medicines, including tolebrutinib for multiple sclerosis, to become available across Europe within 2-3 months following final approval and national reimbursement decisions.

When will tolebrutinib (Cenrifki) be available in Europe?

Following the positive CHMP recommendation, tolebrutinib is expected to receive European Commission approval within 67 days. Actual patient access will depend on individual country pricing negotiations and healthcare system approvals, typically taking 6-12 months.

How does tolebrutinib compare to existing multiple sclerosis treatments?

Tolebrutinib offers a novel BTK inhibitor mechanism that differs from current MS therapies. Clinical trials suggest it may be effective for both relapsing and progressive MS forms, potentially filling treatment gaps for patients who haven’t responded well to existing options.